EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer

Freek R van 't Land iD, Marcella Willemsen, Koen Bezemer iD, Sjoerd H van der Burg, Thierry P P van den Bosch iD, Michail Doukas, Amine Fellah, P Martijn Kolijn iD, Anton W Langerak iD, Miranda Moskie iD, Elise van der Oost iD, Nina E M Rozendaal und 3 weitere

Journal of Clinical Oncology · 10.09.2024 · 42 (26) · 3083-3093

DOI: 10.1200/jco.23.02585 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2024. Verfasst von Freek R van 't Land und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Dendritic Cells. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immunotherapies have shown limited responses in patients with advanced pancreatic cancer. Recently, we reported that dendritic cell (DC)–based immunotherapy induced T-cell responses against pancreatic cancer antigens. The primary objective of this study was to determine the efficacy of DC-based immunotherapy to prevent recurrence of disease. METHODS This was a single-center, open-label, single-arm, combined phase I/II trial. The primary end point was the 2-year recurrence-free survival (RFS) rate. A 2-year RFS rate of ≥60% was defined as a clinically meaningful improvement. We included patients with pancreatic cancer after resection and completion of standard-of-care (SOC) treatment without recurrent disease on cross-sectional imaging. Patients were treated with autologous DCs pulsed with an allogeneic mesothelioma tumor cell lysate, comprising antigens also expressed in pancreatic ductal adenocarcinoma. RESULTS Thirty-eight patients were included in the analysis of the primary end point (47% male, 53% female). The median age was 62 years (IQR, 55-68). Twenty-eight patients (74%) received five DC vaccinations and completed the study protocol. Three patients (8%) received four vaccinations, and seven patients (16%) received three vaccinations. After a median follow-up of 25.5 months, 26 patients (68%) had not developed recurrence of disease. The estimated 2-year RFS was 64%. Vaccination led to the enrichment of circulating activated CD4+ T cells and the detection of treatment-induced immune responses in vitro. T-cell receptor-sequencing analyses of a resected solitary lung metastasis showed influx of vaccine-specific T cells. CONCLUSION This study reached its primary end point of a 2-year RFS rate of ≥60% following pancreatectomy after SOC treatment and adjuvant DC-based immunotherapy in patients with pancreatic cancer. These results warrant a future randomized trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDendritic CellsHumansMaleFemaleMiddle AgedAgedImmunotherapyCancer VaccinesNeoplasm Recurrence, LocalCarcinoma, Pancreatic Ductal

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Amphera B.V., 'S-Hertogenbosch, the Netherlands.
  • Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: Freek R van 't Land, Koen Bezemer, Thierry P P van den Bosch, P Martijn Kolijn, Anton W Langerak, Miranda Moskie, Elise van der Oost, Sara J Baart, Joachim G J V Aerts, Casper H J van Eijck

Zitieren

APA

van 't Land, F. R., Willemsen, M., Bezemer, K., van der Burg, S. H., van den Bosch, T. P. P., Doukas, M., Fellah, A., Kolijn, P. M., Langerak, A. W., Moskie, M., van der Oost, E., Rozendaal, N. E. M., Baart, S. J., Aerts, J. G. J. V., & van Eijck, C. H. J. (2024). Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer. Journal of Clinical Oncology, 42(26), 3083-3093. https://doi.org/10.1200/jco.23.02585

Vancouver

van 't Land FR, Willemsen M, Bezemer K, van der Burg SH, van den Bosch TPP, Doukas M, et al. Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer. Journal of Clinical Oncology. 2024;42(26):3083-3093. doi:10.1200/jco.23.02585

BibTeX
@article{vantLand2024,
  author = {van 't Land, Freek R and Willemsen, Marcella and Bezemer, Koen and van der Burg, Sjoerd H and van den Bosch, Thierry P P and Doukas, Michail and Fellah, Amine and Kolijn, P Martijn and Langerak, Anton W and Moskie, Miranda and van der Oost, Elise and Rozendaal, Nina E M and Baart, Sara J and Aerts, Joachim G J V and van Eijck, Casper H J},
  title = {Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {26},
  pages = {3083--3093},
  doi = {10.1200/jco.23.02585}
}
Kostenlos starten →